Brain metastasis was frequently observed among patients with EGFR-mutant than EGFR-wild-type NSCLC (29.4% vs 19.7%).30 Subgroup analyses of patients with brain metastasis from the LUX-Lung 3 and LUX-Lung 6 have demonstrated a PFS of 11.1 months and 8.2 months, respectively, for first-line afatinib therapy.31 As compared to afatinib, our cohort demonstrated better clinical outcomes with mefatinib therapy with a PFS of 12.8 months, suggesting that first-line mefatinib is a good treatment option for patients who presented with brain metastasis. Here, EGFR is linked to non-small cell lung carcinoma.